CD274 and neoplasm: This study was designed with a hierarchical analysis plan, starting with patients with PD-L1 Tumor cell (TC) expression ≥1% with stages II–IIIA, followed by all stage II–IIIA patients regardless of PD-L1 status, and finally the full intention-to-treat (ITT) population, which included stage IB–IIIA patients.